A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Pelareorep (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 11 Oct 2017 According to an Oncolytics Biotech media release, data from this trial will be presented at the 2017 BIO Investor Forum.
- 19 Sep 2017 According to an Oncolytics Biotech media release, survival data from the study will be presented at the at the Phacilitate Immuno-Oncology Frontiers Conference.
- 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History